OncoMatch/Clinical Trials/NCT06472245
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Is NCT06472245 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including OSE2101 and Docetaxel for patients with non-small cell lung cancer.
Treatment: OSE2101 · Docetaxel · NGS HLAA2 assay — Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control Arm B SoC with docetaxel monotherapy. Stratification factors will be histology (squamous versus non squamous) and ECOG Performance Status (0 versus 1).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Required: HLA-A a2 phenotype
Required: ROS1 wild-type
Allowed: BRAF mutation
Allowed: KRAS g12c
Disease stage
Required: Stage IV
Metastatic disease required
metastatic stage at study entry, not eligible for definite surgery or radiation
Prior therapy
Must have received: immune checkpoint inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Clinical Research Advisors, LLC · Beverly Hills, California
- Clinical Research Advisors - Encino · Encino, California
- Clinical Research Advisors - West Hollywood · Los Angeles, California
- Clinical Research Advisors - Korea Town · Los Angeles, California
- SCL Health - Saint Joseph Hospital Cancer Center · Littleton, Colorado
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06472245 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received immune checkpoint inhibitor.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
Does this trial require HLA-A?
Yes, HLA-A a2 phenotype is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages